Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging for clarity on how Omnicell’s medication-dispensing platforms boost hospital margins—or when its executives last traded shares—means wading through dense disclosures. If you have ever searched “Omnicell insider trading Form 4 transactions” or “Omnicell annual report 10-K simplified,” you know the challenge. Reimbursement nuances, FDA device updates, and SaaS revenue recognition rules hide in hundreds of pages. Investors need “Omnicell SEC filings explained simply,” not another data dump.
Stock Titan solves that problem. Our AI parses every Omnicell quarterly earnings report 10-Q filing, urgent 8-K material events, and even footnotes your accountant flagged. The platform delivers:
- Concise AI-powered summaries for understanding Omnicell SEC documents with AI
- Real-time alerts on Omnicell Form 4 insider transactions—yes, the moment they hit EDGAR
- Side-by-side comparisons that turn Omnicell earnings report filing analysis into a two-minute read
- Instant links to Omnicell proxy statement executive compensation tables and voting matters
Want practical insights? Our dashboards surface which hospital automation segment drives revenue growth in the 10-K, flag R&D spikes tied to next-gen IV compounding, and spotlight Omnicell executive stock transactions Form 4 before contract announcements. You’ll also see Omnicell 8-K material events explained, from FDA clearances to cybersecurity notices. In short, we merge every filing type—10-K, 10-Q, 8-K, Form 4, DEF 14A—into one interface so you can act faster and smarter.
Corey J. Manley, Executive Vice President & Chief Legal/Administrative Officer of Omnicell, Inc. (OMCL), reported a sale of 3,880 shares of Omnicell common stock on 09/12/2025 at a price of $33.25 per share. After the transaction, Mr. Manley beneficially owned 110,653 shares, held directly. The filing notes the sale was made pursuant to a pre-established Rule 10b5-1 trading plan adopted on June 13, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Manley on 09/16/2025.
Omnicell, Inc. (OMCL) Form 3 filed for Radford Harlan Baird, who is listed as an Officer (EVP & Chief Financial Officer) and director-level reporting person. The statement, tied to the 08/26/2025 event date, reports no securities beneficially owned by the reporting person. The filing is signed by an attorney-in-fact on 09/05/2025 and attaches a power of attorney as Exhibit 24.
Omnicell, Inc. announced the appointment of Baird Radford as Executive Vice President and Chief Financial Officer in a press release dated
The filing provides the appointment notice but contains no additional financial figures, background detail about the appointee, effective date beyond the press release date, or commentary on transition plans or compensation.
Omnicell insider transaction: This Form 4 shows that Etta Nchacha, EVP & CFO of Omnicell, disposed of 3,532 shares of Omnicell common stock on 08/15/2025 at a reported price of $31.69 per share. The filing indicates the disposition code "F," and an explanation states the shares were withheld to cover taxes due upon the vesting of restricted stock units.
The filing also reports that Ms. Nchacha beneficially owned 125,176 shares after the transactions, with that balance adjusted to reflect the purchase of 211 shares under the company Employee Stock Purchase Plan on 08/15/2025. The Form is signed by an attorney-in-fact on 08/19/2025.
Randall A. Lipps, Chairman, President and CEO of Omnicell, Inc. (OMCL), reported an internal stock withholding transaction tied to restricted stock unit vesting. The filing shows Mr. Lipps indirectly owns 355,861 shares held in trust with his wife and 8,051 shares held in trust for his children. On 08/15/2025 he had 8,438 shares withheld to cover taxes at a price of $31.69 per share, reducing the reported beneficial ownership to 395,085 shares following the transaction. The form was signed on 08/19/2025 by an attorney-in-fact.
Corey J. Manley, EVP & Chief Legal/Administrative Officer and director of Omnicell, Inc. (OMCL), reported a sale and related ownership update on 08/15/2025. The filing shows 2,792 shares were disposed at a price of $31.69 each, recorded as withholding related to the vesting of restricted stock units to cover taxes. After the transaction and a separate purchase of 199 shares under the company ESPP on 08/15/2025, Mr. Manley beneficially owns 114,533 shares (direct). The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/19/2025.
Omnicell, Inc. (OMCL) insider activity disclosure by Brian H. Nutt. The Form 4 shows transactions on 08/15/2025: 681 shares of common stock were disposed of at $31.69 per share to satisfy tax withholding on vested restricted stock units, leaving 9,905 shares beneficially owned by Mr. Nutt. On the same date he purchased 631 shares under the company Employee Stock Purchase Plan at no listed price in this filing, bringing his post-transaction direct ownership to 17,568 shares. The filing also reports a grant of 7,663 restricted stock units that vest 25% on 08/15/2026 and the remaining 75% quarterly over the following three years.